主题：PET-CT相关资料 -- xtqntd

False-Positive FDG PET Uptakethe Role of PET/CT

Sandra J. Rosenbaum1 Contact Information, Thomas Lind1, Gerald Antoch2 and Andreas Bockisch1

(1) Department of Nuclear Medicine, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany

(2) Department of Radiology, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany

Received: 6 September 2005 Revised: 27 October 2005 Accepted: 18 November 2005 Published online: 17 December 2005

Abstract Positron emission tomography (PET) is a powerful molecular imaging technique for the human body-imaging applications currently available. As altered glucose metabolism is characteristic for many malignancies, FDG-PET is mostly used in oncology for staging and therapy control. Although PET is a [COLOR=blue]sensitive tool for detecting malignancy, FDG uptake is not tumor specific. It can also be seen in healthy tissue or in benign disease as inflammation or posttraumatic repair and could be mistaken for cancer. [/COLOR]The experienced nuclear medicine physician mostly manages to differentiate malignant from non-malignant FDG uptake, but some findings may remain ambiguous. In these cases, the difficulties in differentiating physiologic variants or benign causes of FDG uptake from tumor tissue can often be overcome by combined PET and CT (PET/CT) as anatomic information is added to the metabolic data. Thus, PET/CT improves the diagnostic accuracy compared to PET alone and helps to avoid unnecessary surgery/therapy. However, PET/CT involves other sources of artifacts that may occur when using CT for attenuation correction of PET or by patient motion caused by respiration or bowel movements.

PET-CT较单纯的PET特异性有所提高。但是PET的缺陷并未被完全消除。